Multiple Myeloma an incurable disease, but I have spent the last 25 years in remission using a blend of conventional oncology and evidence-based nutrition, supplementation, and lifestyle therapies from peer-reviewed studies that your oncologist probably hasn't told you about.
Click the orange button to the right to learn more about what you can start doing today.
Conventional oncology has gotten pretty good at putting newly diagnosed multiple myeloma into remission. If you are diagnosed at any stage of MM beyond the earliest of early MM, my experience is that your first priority is to get your MM under control.
Years or even months of conventional MM therapies will lead to common side effects such as CIPN, DVT’s, and others. Some side effects will heal some will not.
The ultimate challenge for the long-term MM survivor is to identify evidence-based, non-conventional therapies such as arsenic trioxide that can balance the toxicity, cost and collateral damage of conventional chemotherapies. Combined with evidence-based supplementation, nutrition, and integrative therapies you can manage your MM (as I have) for years.
I am both a MM survivor and MM cancer coach. Aggressive conventional MM therapies such as induction chemotherapy and an autologous stem cell transplant did little for me beyond giving me short, long-term and late-stage side effects. And my oncologist telling me that she could do nothing more for me after about 3 years…
MM management is not an either/or proposition. I have learned that long-term MMers must use the full spectrum of available MM therapies, both conventional and non-conventional.
Please watch the free webinar linked on the right of the page. Let me know if you have any questions or comments. I look forward to working with you.
“The present study revealed that low doses of arsenic trioxide potentiate the sensitivity of MM cell lines to lenalidomide by upregulating the expression of CRBN, the anti-myeloma target of lenalidomide. The results of the present study demonstrated that low doses of arsenic trioxide upregulated CRBN mRNA level in U266 and RPMI8226 cell lines…”
Of the patients that completed the treatment, objective responses were observed despite suboptimal dosing and previous bortezomib treatment failure. Tolerability was observed in most patients as discontinuation was not due to treatment toxicities, but due to aggressiveness of disease. Further studies are warranted with a larger patient population to effectively determine the effectiveness of AAV in relapsed/refractory multiple myeloma…”
“Arsenic has been used since ancient times as a therapeutic agent. However, until recently its use in modern medicine has been restricted to the treatment of a limited number of parasitic infections.
Investigations of this agent have demonstrated that its efficacy in APL and preclinical tumor models is dependent upon a number of mechanisms, including induction of apoptosis, effects on cellular differentiation, cell cycling, and tumor angiogenesis. Subsequent preclinical studies showed the significant activity of arsenic trioxide in multiple myeloma (MM).
Based on this, in a phase II trial, we have evaluated the activity of arsenic trioxide in 14 patients with relapsed MM, refractory to conventional salvage therapy. With the dose and schedule used, treatment with arsenic trioxide produced responses in three patients and prolonged stable disease in a fourth patient, with the longest response lasting 6 weeks. Although treatment was reasonably well tolerated, in these patients with extensive prior therapy, 11 developed cytopenia, five associated with infectious complications and three developed deep vein thromboses. The results of this small trial support further investigation of this novel drug for the treatment of patients with relapsed or refractory MM.”
“Arsenic trioxide has shown great promise in the treatment of patients with relapsed or refractory acute promyelocytic leukemia (APL). In clinical trials, arsenic trioxide induces complete remission in 87% of patients and molecular remission in 83% of patients. Two-year overall and relapse-free survival estimates are 63% and 49%, respectively. Treatment with arsenic trioxide may be associated with the APL differentiation syndrome, leukocytosis, and electrocardiographic abnormalities. The expanded use of arsenic trioxide in APL for postremission therapy, in conjunction with transplantation, and in patients with newly diagnosed APL is under investigation. The multiple mechanisms of action of arsenic trioxide suggest that it may have antitumor activity in malignancies other than APL and that it may be used in combination with other agents to expand its potential use.“